Zealand Pharma A/S (NASDAQ: ZEAL) announced that Boehringer Ingelheim's survodutide achieved significant weight loss results in a phase 3 clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE